Εμφάνιση απλής εγγραφής

dc.creatorKoureas M., Kirgou P., Amoutzias G., Hadjichristodoulou C., Gourgoulianis K., Tsakalof A.en
dc.date.accessioned2023-01-31T08:45:31Z
dc.date.available2023-01-31T08:45:31Z
dc.date.issued2020
dc.identifier10.3390/metabo10080317
dc.identifier.issn22181989
dc.identifier.urihttp://hdl.handle.net/11615/75319
dc.description.abstractThe aim of the present study was to investigate the ability of breath analysis to distinguish lung cancer (LC) patients from patients with other respiratory diseases and healthy people. The population sample consisted of 51 patients with confirmed LC, 38 patients with pathological computed tomography (CT) findings not diagnosed with LC, and 53 healthy controls. The concentrations of 19 volatile organic compounds (VOCs) were quantified in the exhaled breath of study participants by solid phase microextraction (SPME) of the VOCs and subsequent gas chromatography-mass spectrometry (GC-MS) analysis. Kruskal–Wallis and Mann–Whitney tests were used to identify significant differences between subgroups. Machine learning methods were used to determine the discriminant power of the method. Several compounds were found to differ significantly between LC patients and healthy controls. Strong associations were identified for 2-propanol, 1-propanol, toluene, ethylbenzene, and styrene (p-values < 0.001–0.006). These associations remained significant when ambient air concentrations were subtracted from breath concentrations. VOC levels were found to be affected by ambient air concentrations and a few by smoking status. The random forest machine learning algorithm achieved a correct classification of patients of 88.5% (area under the curve—AUC 0.94). However, none of the methods used achieved adequate discrimination between LC patients and patients with abnormal computed tomography (CT) findings. Biomarker sets, consisting mainly of the exogenous monoaromatic compounds and 1-and 2-propanol, adequately discriminated LC patients from healthy controls. The breath concentrations of these compounds may reflect the alterations in patient’s physiological and biochemical status and perhaps can be used as probes for the investigation of these statuses or normalization of patient-related factors in breath analysis. © 2020 by the authors.en
dc.language.isoenen
dc.sourceMetabolitesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85090651697&doi=10.3390%2fmetabo10080317&partnerID=40&md5=2daf71ed33cc3fe5b2cf5ade9fb110c4
dc.subject2 butanoneen
dc.subject2 propanolen
dc.subjectacetoneen
dc.subjectaromatic compounden
dc.subjectbutanolen
dc.subjectbutyric acid ethyl esteren
dc.subjectcyclohexanoneen
dc.subjectethylbenzeneen
dc.subjecthexanalen
dc.subjectisopreneen
dc.subjectnonanalen
dc.subjectoctaneen
dc.subjectoctanolen
dc.subjectpropanolen
dc.subjectstyreneen
dc.subjectthiopheneen
dc.subjecttolueneen
dc.subjectvolatile organic compounden
dc.subjectambient airen
dc.subjectArticleen
dc.subjectbody massen
dc.subjectbreath analysisen
dc.subjectbronchoscopyen
dc.subjectchemical, physical and mathematical phenomenaen
dc.subjectcomputer assisted tomographyen
dc.subjectcontrolled studyen
dc.subjectcurrent smokeren
dc.subjectcytologyen
dc.subjectex-smokeren
dc.subjectexpired airen
dc.subjectfemaleen
dc.subjectgas chromatographyen
dc.subjecthumanen
dc.subjectKruskal Wallis testen
dc.subjectlung canceren
dc.subjectlung diseaseen
dc.subjectmachine learningen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectnormal humanen
dc.subjectsmoking habiten
dc.subjectsolid phase microextractionen
dc.subjecttransbronchial aspirationen
dc.subjecttransbronchial biopsyen
dc.subjectMDPI AGen
dc.titleTarget analysis of volatile organic compounds in exhaled breath for lung cancer discrimination from other pulmonary diseases and healthy personsen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής